Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

References

• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524–6534.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, . Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–274.
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336–347.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467–477.
   PubMed Web of Science ®Google Scholar
• Mir MA, Agrewala JN. Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets 2008;12:969–979.
   PubMed Web of Science ®Google Scholar
• Weber J. Review: Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864–872.
   PubMed Web of Science ®Google Scholar
• Dong HD, Zhu GF, Tamada K, . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365–1369.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, . The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239–245.
   PubMed Web of Science ®Google Scholar
• Fu J, Zhang P, Su DM, . Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008;45:1470–1476.
   PubMed Web of Science ®Google Scholar
• Kondo A, Yamashita T, Tamura H, . Interferon-{gamma} and tumor necrosis factor-{alpha} induce an immunoinhibitory molecule, B7-H1, via nuclear factor {kappa}B activation in blasts in myelodysplastic syndromes. Blood 2010;116:1124–1131.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–772.
   PubMed Web of Science ®Google Scholar
• Ishida M, Iwai Y, Tanaka Y, . Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 2002;84:57–62.
   PubMed Web of Science ®Google Scholar
• Parekh VV, Lalani S, Kim S, . PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009;182:2816–2826.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813–824.
   PubMed Web of Science ®Google Scholar
• Wu CP, Zhu YB, Jiang JT, . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19–24.
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang XY, Qiu SJ, . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971–979.
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, . The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190–198.
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol 1997;10:859–863.
   PubMed Web of Science ®Google Scholar
• Breton G, Yassine-Diab B, Cohn L, . siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals. J Clin Immunol 2009;29:637–645.
   PubMed Web of Science ®Google Scholar
• Ewbank J, Vivier E. Innate immunity. Totowa, NJ: Humana Press; 2008.
   Google Scholar
• Ausubel FM. Short protocols in molecular biology: a compendium of methods from current protocols in molecular biology. 5th ed. New York: Wiley; 2002.
   Google Scholar
• Yang Y, Lu N, Zhou J, . Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology 2008;47: 1299–1310.
   PubMed Web of Science ®Google Scholar
• Davis PK, Ho A, Dowdy SF. Biological methods for cell-cycle synchronization of mammalian cells. Biotechniques 2001;30:1322–1326, 1328, 1330–1331.
   PubMed Web of Science ®Google Scholar
• la Riviere G, Schipper CA, Collard JG, . Invasiveness in hepatocyte and fibroblast monolayers and metastatic potential of T-cell hybridomas in mice. Cancer Res 1988;48:3405–3410.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Bakan CE, Mishra A, . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody. Blood 2010;116:2286–2294.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Jia L, Ke X, Wang J. Expression of B7 costimulator in eight human malignant hematological cell lines and its significance. Chin J Hematol 2002;23:345–348.
   Google Scholar
• Andorsky DJ, Yamada R, Said JW, . Programmed death ligand 1 (PD-L1) is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 2011;17:4232–4244.
   PubMed Web of Science ®Google Scholar
• Sierro SR, Donda A, Perret R, . Combination of lentivector immunization and low dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011;41:2217–2228.
   PubMed Web of Science ®Google Scholar
• Karwacz K, Bricogne C, MacDonald D, . PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8 + T cells. EMBO Mol Med 2011;3:581–592.
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H, . Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089–1096.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Koyanagi A, . Blockade of B7-H1 on macrophages suppresses CD4 + T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 2005;175:1586–1592.
   PubMed Web of Science ®Google Scholar
• Azuma T, Yao S, Zhu G, . B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111:3635–3643.
   PubMed Web of Science ®Google Scholar